Canada's AbCellera Q3 revenue beats analyst estimates
Canada's AbCellera Q3 revenue beats analyst estimates
Overview
Canada biotech firm's Q3 revenue rose, beating analyst expectations
Net loss narrowed to $40.8 mln from $57.1 mln a year earlier
Company completed $200 mln capital raise, boosting liquidity to over $890 mln
Outlook
AbCellera expects to initiate late-stage development for ABCL635 in menopausal VMS in 2027
Company plans clinical trials for ABCL635 in breast and prostate cancer-related VMS in 2027
Result Drivers
CLINICAL TRIAL PROGRESS - Co highlighted positive top-line Phase 2 results for ABCL635 and Phase 1 results for ABCL575 as key milestones in the qtr
PIPELINE EXPANSION - Three new programs (ABCL992, ABCL385, ABCL646) advanced to IND-enabling activities during the qtr
LOWER OPERATING EXPENSES - R&D and SG&A expenses both declined compared to prior year, contributing to narrower net loss
Company press release: ID:nBw4RJVsha
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $10.6 mln | $8.42 mln (11 Analysts) |
Q3 Loss Per Share |
| $0.13 |
|
Q3 Net Loss |
| $40.8 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for AbCellera Biologics Inc. is $15.00, about 26.3% above its November 6 closing price of $11.88
Reuters Recommended Reads
Nov 9 - Bicara Therapeutics Q3 net loss widens on higher R&D costs
Nov 9 - ADC Therapeutics Q3 revenue beats estimates on sales volume
Nov 9 - Ionis Pharmaceuticals Q3 revenue rises 55%
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on AbCellera Biologics
See all newsAbCellera Biologics Inc. reports results for the quarter ended September 30 - Earnings Summary
Canada's AbCellera Q3 revenue beats analyst estimates
Factbox: Pharma sector doubles down on AI to slash costs, timelines
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce